Literature DB >> 28089373

Clinical parameters affecting dapagliflozin response in patients with type 2 diabetes.

J-Y Lee1, G Kim1, S R Kim1, Y-H Lee2, B-W Lee2, B-S Cha2, E S Kang3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28089373     DOI： 10.1016/j.diabet.2016.11.005

Source DB:  PubMed          Journal:  Diabetes Metab        ISSN： 1262-3636            Impact factor:   6.041


× No keyword cloud information.
  4 in total

Review 1.  Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus.

Authors:  André J Scheen
Journal:  Nat Rev Endocrinol       Date:  2020-08-27       Impact factor: 43.330

2.  Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea.

Authors:  Eugene Han; Ari Kim; Sung Jae Lee; Je-Yon Kim; Jae Hyeon Kim; Woo Je Lee; Byung-Wan Lee
Journal:  Diabetes Ther       Date:  2018-07-11       Impact factor: 2.945

3.  Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors.

Authors:  Ji Yeon Lee; Yongin Cho; Minyoung Lee; You Jin Kim; Yong Ho Lee; Byung Wan Lee; Bong Soo Cha; Eun Seok Kang
Journal:  Diabetes Metab J       Date:  2019-01-25       Impact factor: 5.376

4.  Blood glucose levels and bodyweight change after dapagliflozin administration.

Authors:  Hyunah Kim; Seung-Hwan Lee; Hyunyong Lee; Hyeon Woo Yim; Jae-Hyoung Cho; Kun-Ho Yoon; Hun-Sung Kim
Journal:  J Diabetes Investig       Date:  2021-02-28       Impact factor: 4.232
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.